Outcome comparison from various trials for teenage acute lymphoblastic leukemia (ALL) patients (≥10y).
| Trial . | Age Range . | n . | % of Total Study Population . | 5y-pEFS (SE) . | Ref. . |
|---|---|---|---|---|---|
| Abbreviations: pEFS, probability for event-free survival; AIEOP, Associazione Italiana Ematologia Oncologia Pediatrica; BFM, Berlin-Frankfurt-Münster; CCG, Children’s Cancer Group; COALL, Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia; DFCI, Dana-Farber Cancer Institute; EORTC-CLCG, European Organisation for Research and Treatment of Cancer–Children Cooperative Leukemia Group; SJCRH, St Jude’s Cancer Research Hospital; NOPHO, Nordic Society for Pediatric Hematology;TCCSG, Tokyo Children’s Cancer Study Group; UKALL, United Kingdom Acute Lymphoblastic Leukemia | |||||
| AIEOP 91 | 10–17y | 190 | 15.9 | 52.5 (3.6) | 1 |
| BFM 90 | 10–18y | 386 | 17.7 | 64.4 (2.5) | 3 |
| CCG 1800 series | ≥ 10y | 1107 | 21.6 | 66.0 (2.0) | 2 |
| COALL 92 | 10–18y | 104 | 19.3 | 70.5 (4.6) | 84 |
| DFCI 91-01 | 10–18y | 69 | 18.3 | 79.0 (5.0) | 85 |
| EORTC-CLCG 58881 | 10–18y | 361 | 17.5 | 58.2 (2.9) | 4 |
| NOPHO 92-98 | 10–15y | 179 | 15.7 | 72.3 (3.6) | 5 |
| SJCRH 13A | 10–18y | 43 | 26.1 | 55.7 (7.6) | 68 |
| TCCSG L92-13 | ≥ 10y | 83 | 23.9 | 57.0 (5.8) | 86 |
| UKALL XI | 10–14y | 316 | 15.1 | 62 (2.9) | 87 |
| Trial . | Age Range . | n . | % of Total Study Population . | 5y-pEFS (SE) . | Ref. . |
|---|---|---|---|---|---|
| Abbreviations: pEFS, probability for event-free survival; AIEOP, Associazione Italiana Ematologia Oncologia Pediatrica; BFM, Berlin-Frankfurt-Münster; CCG, Children’s Cancer Group; COALL, Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia; DFCI, Dana-Farber Cancer Institute; EORTC-CLCG, European Organisation for Research and Treatment of Cancer–Children Cooperative Leukemia Group; SJCRH, St Jude’s Cancer Research Hospital; NOPHO, Nordic Society for Pediatric Hematology;TCCSG, Tokyo Children’s Cancer Study Group; UKALL, United Kingdom Acute Lymphoblastic Leukemia | |||||
| AIEOP 91 | 10–17y | 190 | 15.9 | 52.5 (3.6) | 1 |
| BFM 90 | 10–18y | 386 | 17.7 | 64.4 (2.5) | 3 |
| CCG 1800 series | ≥ 10y | 1107 | 21.6 | 66.0 (2.0) | 2 |
| COALL 92 | 10–18y | 104 | 19.3 | 70.5 (4.6) | 84 |
| DFCI 91-01 | 10–18y | 69 | 18.3 | 79.0 (5.0) | 85 |
| EORTC-CLCG 58881 | 10–18y | 361 | 17.5 | 58.2 (2.9) | 4 |
| NOPHO 92-98 | 10–15y | 179 | 15.7 | 72.3 (3.6) | 5 |
| SJCRH 13A | 10–18y | 43 | 26.1 | 55.7 (7.6) | 68 |
| TCCSG L92-13 | ≥ 10y | 83 | 23.9 | 57.0 (5.8) | 86 |
| UKALL XI | 10–14y | 316 | 15.1 | 62 (2.9) | 87 |